Hangzhou Chungyo Chemicals Co., Ltd.

Semaglutide is a new generation of GLP-1 (glucagon-like peptide-1) analogue developed by NovoNordisk in Denmark, which is a long-acting dosage form developed based on the basic structure of liraglutide, which has a better effect on the treatment of type 2 diabetes. Novo Nordisk has completed six Phase IIIa studies of semaglutide injection, and has submitted a new drug registration application for semaglutide weekly injection to the U.S. Food and Drug Administration (FDA) on December 5, 2016, and a marketing authorization application (MAA) to the European Medicines Agency (EMA). On the other hand, the once-daily oral formulation of semaglutide is currently in phase III clinical trials.